Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natural Progesterone for Recurrent Glioblastoma
NCT05091866Phase 1Terminated
- Sponsor
- Emory University
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of progesterone in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Emory University. Primary endpoints: Pharmacokinetics of natural progesterone at Day 8, Incidence of adverse events up to 2 years and 1 more. Started Apr 2022; status: terminated.
02
Drugs
progesterone
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT05091866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091866.